Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
convalescent plasma (Ministry of Health and Population)
- Development stage
- Unknown
- Lead developer
- Ministry of Health and Population
- Administration
- Intravenous
01
Overview
Convalescent plasma is a biologic therapy derived from the blood of individuals who have recovered from COVID-19. It contains polyclonal antibodies, including neutralizing antibodies that specifically target the SARS-CoV-2 virus, primarily its spike and nucleocapsid proteins. The Ministry of Health and Population (MOHP) in Egypt investigated this therapy in Phase 3 clinical trials to treat severe and critically ill COVID-19 patients, focusing on the timing of administration (early versus late). As a form of passive immunotherapy, it aims to reduce viral load and improve clinical outcomes by providing immediate, exogenous antibodies to patients whose own immune systems may not have yet produced a sufficient response.
- Other names
- COVID-19 convalescent plasmaCOVID19 convalescent plasmaCOVID 19 convalescent plasmaCCPconvalescent plasma-Ministry of Health and Population, Egypt-COVID-19
02
Targets
RBD (SARS-CoV-2 spike receptor-binding domain)S1-NTD (SARS-CoV-2 spike S1 N-terminal domain)S2 (SARS-CoV-2 spike S2 subunit)N (Nucleocapsid protein)
Beyond the preview
Go deeper on convalescent plasma (Ministry of Health and Population).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on convalescent plasma (Ministry of Health and Population).